INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α (brand name: Yinuoqing®), China's first domestically developed ultra-long-acting human GLP-1 receptor agonist (GLP-1RA), has been included in the 2025 National Reimbursement Drug List for "blood glucose control in adult type 2 diabetes patients," effective January 1, 2026. This marks a significant step in expanding access to innovative diabetes treatments in China.

The National Primary Diabetes Prevention and Management Guidelines (2025) listed Esupaglutide α as a weekly GLP-1RA injectable, providing policy and regulatory support for its use in primary healthcare institutions. The guidelines highlight GLP-1RA as a key treatment option for adult type 2 diabetes (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD) or its risk factors, heart failure, chronic kidney disease (CKD), as well as overweight or obese patients requiring weight management.